ROIV (Roivant Sciences) Asset Impairment Charge: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROIV Roivant Sciences Ltd ROIV
51 GF Score
Price $34.71
GF Value $6.62
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Asset Impairment Charge?

Roivant Sciences ROIV -7.64% 51 Asset Impairment Charge is $0.00 Mil as of Jun. 2026. GuruFocus rates ROIV with a GF Score™ of 51/100 and a GF Value™ of $6.62 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Roivant Sciences's Asset Impairment Charge for the three months ended in Jun. 2026 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Roivant Sciences Asset Impairment Charge Related Terms

Roivant Sciences Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Asset Impairment Charge Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Asset Impairment Charge
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 15.59

Roivant Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROIV
51GF Score
Roivant Sciences Ltd ROIV
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

What does a Asset Impairment Charge of $0.00 Mil mean?
Roivant Sciences (ROIV) has a Asset Impairment Charge of $0.00 Mil as of Jun. 2026.
Is Roivant Sciences' Asset Impairment Charge too high?
Roivant Sciences' current Asset Impairment Charge is $0.00 Mil. Overall, Roivant Sciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Asset Impairment Charge compare to RPRX and INCY?
Roivant Sciences' Asset Impairment Charge of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Roivant Sciences's current Asset Impairment Charge is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.62, compared to a current price of $34.71 — trading 424.3% above its estimated fair value. The current Asset Impairment Charge is $0.00 Mil. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Asset Impairment Charge is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (ROIV) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of $34.71 is trading 424.3% above its estimated GF Value™ of $6.62. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for ROIV:

  • Asset Impairment Charge: $0.00 Mil
  • GF Value™: $6.62 vs. price of $34.71 (424.3% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges 87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score

Get the complete analysis for ROIV

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.71
Price
$6.62
GF Value